PKMYT1 Antibody

What is PKMYT1 and what cellular functions does it regulate?

PKMYT1 (Protein Kinase, Membrane Associated Tyrosine/Threonine 1) is a membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase that plays a critical role in cell cycle regulation. The protein is approximately 54.5 kilodaltons in mass and functions primarily as a negative regulator of cell cycle progression . PKMYT1 operates in the G2/M checkpoint of the cell cycle by phosphorylating and inhibiting the activity of CDK1 (Cyclin-Dependent Kinase 1), preventing premature entry into mitosis. This regulatory mechanism is essential for maintaining genomic integrity by ensuring cells do not enter mitosis with damaged or incompletely replicated DNA. In cancer contexts, PKMYT1 has been observed to promote proliferation, migration, invasion, and suppress apoptosis in various cancer cell lines, particularly in triple-negative breast cancer (TNBC) .

What are the common applications for PKMYT1 antibodies in research?

PKMYT1 antibodies are valuable research tools employed across multiple experimental techniques. The primary applications include:

• Western Blotting (WB): For detecting and quantifying PKMYT1 protein expression levels in cell or tissue lysates

• Immunohistochemistry (IHC): For visualizing PKMYT1 expression patterns in tissue sections

• ELISA: For quantitative measurement of PKMYT1 in various samples

• Flow Cytometry (FCM): For analyzing PKMYT1 expression in individual cells

• Immunofluorescence (IF): For subcellular localization studies of PKMYT1

These applications are critical for investigating PKMYT1's role in normal cellular processes and pathological conditions, particularly in cancer research where PKMYT1 expression may serve as a potential biomarker or therapeutic target.

How do researchers validate the specificity of PKMYT1 antibodies?

Validating antibody specificity is crucial for ensuring reliable experimental results. For PKMYT1 antibodies, researchers typically employ multiple validation strategies:

• Positive and negative control samples: Using cell lines with known high (e.g., MDA-MB-231, BT-549) and low (e.g., MCF-10A) PKMYT1 expression levels

• siRNA knockdown validation: Comparing antibody detection between samples with normal PKMYT1 expression and those treated with PKMYT1-targeting siRNA. A specific antibody will show reduced signal in knockdown samples

• Blocking peptide competition: Pre-incubating the antibody with a specific peptide corresponding to the immunogen sequence (e.g., amino acids 900-1101 for certain antibodies) should abolish specific binding

• Cross-reactivity testing: Evaluating antibody reactivity against samples from different species to confirm specificity for the intended target species (human, mouse, etc.)

• Multi-antibody concordance: Comparing results obtained with different antibodies targeting distinct epitopes of PKMYT1

These validation approaches help ensure that experimental observations genuinely reflect PKMYT1 biology rather than non-specific interactions.

What are the optimal conditions for using PKMYT1 antibodies in Western blotting?

Achieving optimal results with PKMYT1 antibodies in Western blotting requires careful attention to several experimental parameters:

• Sample preparation:

  • Harvest cells at 80-90% confluence

  • Lyse cells in RIPA buffer supplemented with protease and phosphatase inhibitors

  • Include DTT or β-mercaptoethanol in loading buffer to reduce disulfide bonds

• Gel electrophoresis and transfer conditions:

  • Use 10-12% polyacrylamide gels for optimal separation around the 54.5 kDa range

  • Transfer to PVDF membranes (rather than nitrocellulose) for enhanced protein binding

  • Transfer at constant 100V for 90 minutes in cold transfer buffer with 20% methanol

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Incubate primary antibody at 1:500-1:2000 dilution overnight at 4°C

  • Wash thoroughly (3 × 10 minutes) with TBST before secondary antibody incubation

  • Use HRP-conjugated secondary antibodies at 1:5000-1:10000 dilution for 1 hour at room temperature

• Detection considerations:

  • Enhanced chemiluminescence (ECL) is generally sufficient for detection

  • For quantitative analysis, ensure exposures remain in the linear range

  • Include appropriate loading controls (GAPDH, β-actin, or total protein staining)

For phospho-specific PKMYT1 antibodies, such as those targeting pThr495, additional considerations include using phosphatase inhibitors throughout the procedure and potentially using phospho-blocking solutions.

How should PKMYT1 antibodies be optimized for immunohistochemistry applications?

Optimizing immunohistochemistry protocols for PKMYT1 detection requires systematic evaluation of multiple parameters:

• Tissue processing and antigen retrieval:

  • Formalin-fixed paraffin-embedded (FFPE) tissues typically require heat-induced epitope retrieval

  • Test multiple pH conditions: citrate buffer (pH 6.0) and EDTA buffer (pH 9.0)

  • Perform antigen retrieval for 15-20 minutes at 95-98°C

• Blocking and antibody conditions:

  • Block endogenous peroxidase with 3% H₂O₂ for 10 minutes

  • Apply protein block (2-5% BSA or serum) for 30-60 minutes

  • Test a range of primary antibody dilutions (1:100-1:500) with overnight incubation at 4°C

  • Use appropriate detection systems (e.g., HRP-polymer systems) with 3,3'-diaminobenzidine (DAB) as chromogen

• Controls and validation:

  • Include positive control tissues (breast cancer tissue with known PKMYT1 overexpression)

  • Include negative controls (omission of primary antibody)

  • Consider using cell pellets from siRNA knockdown experiments as additional controls

• Scoring and interpretation:

  • Develop consistent scoring criteria (intensity, percentage of positive cells)

  • Consider both cytoplasmic and nuclear staining patterns for PKMYT1

  • Validate findings with orthogonal methods (e.g., qRT-PCR, Western blotting)

Pilot studies with a small set of samples are recommended to establish optimal conditions before proceeding to larger studies.

What strategies can researchers use to troubleshoot non-specific binding of PKMYT1 antibodies?

Non-specific binding is a common challenge when working with antibodies. For PKMYT1 antibodies, researchers can employ several troubleshooting strategies:

• Antibody optimization:

  • Test multiple antibody concentrations to identify optimal signal-to-noise ratio

  • Increase washing duration and frequency (4-5 washes of 10 minutes each)

  • Try different blocking agents (milk, BSA, normal serum)

  • Evaluate different antibody clones targeting different epitopes of PKMYT1

• Sample preparation refinements:

  • Ensure complete protein denaturation for Western blotting

  • For IHC, optimize fixation time and antigen retrieval conditions

  • Add detergents (0.1-0.3% Triton X-100) to reduce hydrophobic interactions

• Validation approaches:

  • Perform peptide competition assays using the immunizing peptide

  • Compare results with PKMYT1 knockdown or knockout samples

  • Evaluate reciprocal co-immunoprecipitation to confirm specific interactions

• Advanced techniques:

  • Consider pre-adsorption of antibody against tissues/lysates from PKMYT1-depleted samples

  • For Western blotting, use gradient gels to better separate proteins of similar molecular weights

  • For IHC, consider tyramide signal amplification to allow more dilute antibody concentrations

Thorough documentation of optimization experiments is essential for reproducibility and troubleshooting.

What methods are most effective for studying PKMYT1's functional role in cancer cell biology?

Investigating PKMYT1's functional role in cancer requires complementary approaches:

• Gene expression modulation:

  • siRNA-mediated knockdown: Using sequences targeting PKMYT1 (e.g., sense 5'-GGACAGCAGCGGAUGUGUUTT-3', antisense 5'-GCGGUAAAGCGUUCCAUGUTT-3')

  • shRNA for stable knockdown: For long-term studies and in vivo experiments

  • CRISPR-Cas9 gene editing: For complete knockout studies

  • Overexpression systems: For gain-of-function studies using tagged constructs

• Functional assays:

  • Proliferation assays: CCK-8, MTT, or BrdU incorporation

  • Colony formation assays: For clonogenic potential

  • Migration and invasion assays: Transwell and wound healing assays

  • Apoptosis detection: Flow cytometry with Annexin V/PI staining

  • Cell cycle analysis: Propidium iodide staining and flow cytometry

• Molecular mechanism investigations:

  • Co-immunoprecipitation: To identify protein interaction partners

  • Phosphorylation-specific antibodies: To study regulatory modifications

  • Chromatin immunoprecipitation (ChIP): For transcriptional regulation studies

  • RNA-seq and proteomics: For comprehensive pathway analysis

• In vivo models:

  • Xenograft models: For tumorigenicity and metastasis

  • Patient-derived xenografts: For translation to clinical scenarios

  • Conditional knockout mouse models: For tissue-specific studies

The combination of these approaches provides comprehensive insights into PKMYT1's role in cancer cell biology, from molecular mechanisms to phenotypic consequences.

How can researchers distinguish between the effects of PKMYT1 inhibition and off-target effects in experimental studies?

Differentiating specific PKMYT1 inhibition from off-target effects is crucial for accurate interpretation of experimental results:

• Multiple inhibition approaches:

  • Compare results from different siRNA/shRNA sequences targeting PKMYT1

  • Validate with CRISPR-Cas9 knockout studies

  • Use small molecule inhibitors with varying selectivity profiles

  • Perform rescue experiments with siRNA-resistant PKMYT1 expression constructs

• Dose-response relationships:

  • Establish dose-dependency for both target inhibition and biological effects

  • Determine IC50 values for PKMYT1 inhibition vs. off-target effects

  • Compare molecular and phenotypic changes across concentration ranges

• Pathway validation:

  • Monitor direct PKMYT1 substrates (e.g., CDK1 phosphorylation states)

  • Assess cell cycle markers to confirm expected mechanistic effects

  • Compare effects to known PKMYT1 functions in cell cycle regulation

• Control experiments:

  • Include non-targeting controls with similar chemical structures

  • Test effects in cell lines with PKMYT1 knockout/knockdown

  • Perform parallel experiments with inhibitors of related kinases

• Advanced validation techniques:

  • Phosphoproteomic analysis to comprehensively assess kinase activity

  • CRISPR screens to identify synthetic lethal interactions

  • Computational approaches to predict off-target binding

The combined evidence from these approaches strengthens confidence in attributing observed effects specifically to PKMYT1 inhibition.

How can phospho-specific PKMYT1 antibodies be utilized to investigate cell cycle regulation?

Phospho-specific antibodies targeting PKMYT1 provide unique insights into its regulation and function:

• Key phosphorylation sites:

  • pThr495: Critical regulatory site affecting PKMYT1 kinase activity

  • pSer83: Important for protein-protein interactions and localization

  • Additional sites modulating function and stability

• Experimental applications:

  • Cell cycle synchronization: Analyze phosphorylation dynamics through different cycle phases

  • Drug treatment studies: Assess how CDK inhibitors or other cell cycle modulators affect PKMYT1 phosphorylation

  • DNA damage response: Investigate phosphorylation changes following genotoxic stress

• Methodological considerations:

  • Phosphatase inhibitor cocktails are essential in all buffers

  • Rapid sample processing prevents dephosphorylation

  • Validation with phosphatase treatment as negative control

  • Comparison with total PKMYT1 antibodies for normalization

• Advanced techniques:

  • Phospho-flow cytometry: For single-cell analysis of phosphorylation

  • Proximity ligation assay (PLA): To visualize interactions dependent on phosphorylation

  • FRET-based sensors: For real-time monitoring of phosphorylation dynamics

These approaches provide mechanistic insights into how PKMYT1 phosphorylation status correlates with cell cycle progression and response to cellular stresses.

What approaches can be used to study PKMYT1's role in tumor microenvironment interactions?

Understanding PKMYT1's involvement in tumor microenvironment interactions requires specialized techniques:

• Co-culture systems:

  • Cancer cells with fibroblasts, immune cells, or endothelial cells

  • 3D organoid models incorporating multiple cell types

  • Conditioned media experiments to assess paracrine signaling

• Tissue-based analyses:

  • Multiplex immunohistochemistry: Co-localization of PKMYT1 with immune cell markers

  • Digital spatial profiling: Quantitative assessment of PKMYT1 in relation to microenvironment components

  • Single-cell RNA sequencing: Cell type-specific expression patterns

• Functional assessments:

  • Migration and invasion assays using conditioned media

  • Extracellular matrix remodeling studies

  • Angiogenesis assays with PKMYT1-modified cancer cells

• Immune interaction studies:

  • T-cell cytotoxicity assays with PKMYT1-modulated cancer cells

  • Analysis of PD-L1 expression in relation to PKMYT1 levels

  • Assessment of immunotherapy response biomarkers

• In vivo approaches:

  • Syngeneic mouse models with intact immune systems

  • Humanized mouse models for human-specific interactions

  • Intravital microscopy for real-time visualization of interactions

These methodologies help decipher how PKMYT1 in cancer cells influences and is influenced by various components of the tumor microenvironment.

How can researchers integrate PKMYT1 antibody data with other -omics approaches for comprehensive pathway analysis?

Integrating antibody-based PKMYT1 data with multi-omics approaches provides holistic insights:

• Multi-level data integration:

  • Correlate protein expression (antibody-based) with mRNA expression (RNA-seq)

  • Connect PKMYT1 protein levels with genomic alterations (copy number, mutations)

  • Relate PKMYT1 status to global phosphoproteome changes

  • Associate with metabolomic profiles to understand metabolic consequences

• Analytical approaches:

  • Pathway enrichment analysis incorporating PKMYT1 antibody data

  • Network analysis to identify PKMYT1-centered functional modules

  • Machine learning algorithms to predict outcomes based on integrated datasets

  • Systems biology modeling of cell cycle regulation

• Technical considerations:

  • Normalize antibody data appropriately for integration with other data types

  • Account for different dynamic ranges across platforms

  • Consider temporal aspects of different molecular events

  • Validate key findings with orthogonal techniques

• Visualization and interpretation:

  • Develop multi-dimensional visualizations of PKMYT1 in pathway contexts

  • Use causal inference methods to establish directionality

  • Create predictive models incorporating PKMYT1 status

  • Design experimental validation of computationally predicted relationships

Such integrated approaches have revealed PKMYT1's connections to cell cycle regulation, DNA damage response pathways, and potential involvement in therapy resistance mechanisms in cancer.

How can PKMYT1 antibodies be used to develop biomarker assays for clinical applications?

Developing PKMYT1-based biomarker assays requires rigorous standardization:

• Assay development considerations:

  • Selection of highly specific and reproducible antibodies

  • Optimization for different sample types (FFPE tissues, liquid biopsies)

  • Development of quantitative scoring systems

  • Establishment of positive/negative cutoff values

• Clinical validation approaches:

  • Retrospective studies on archived samples with outcome data

  • Prospective validation in clinical trial settings

  • Comparison with established biomarkers

  • Analysis of predictive vs. prognostic value

• Technical platforms:

  • IHC on tissue microarrays for high-throughput analysis

  • Automated image analysis for standardized quantification

  • Multiplex assays combining PKMYT1 with other markers

  • ELISA or other solution-based assays for circulating PKMYT1

• Quality control measures:

  • Inter-laboratory validation studies

  • Use of reference standards across batches

  • Regular proficiency testing

  • Compliance with regulatory requirements for clinical tests

These approaches support the development of PKMYT1 as a clinically useful biomarker, particularly for identifying aggressive breast cancer subtypes that might benefit from specific therapeutic strategies.

What experimental evidence supports targeting PKMYT1 as a therapeutic strategy in cancer?

The therapeutic potential of targeting PKMYT1 is supported by multiple lines of evidence:

• Functional studies demonstrating oncogenic roles:

  • siRNA knockdown of PKMYT1 inhibits proliferation and colony formation in TNBC cell lines (MDA-MB-231, BT-549)

  • PKMYT1 depletion significantly reduces migration and invasion capabilities

  • Knockdown increases apoptosis in cancer cells

  • Effects observed across multiple cancer types, suggesting broad therapeutic potential

• Mechanistic rationale:

  • PKMYT1 regulates critical cell cycle checkpoints

  • Cancer cells often rely on specific cell cycle regulators for survival

  • Correlation with genomic instability markers suggests potential synthetic lethality

  • Association with response to existing therapies suggests combination potential

• Preclinical evidence:

  • Xenograft studies showing tumor growth inhibition with PKMYT1 targeting

  • Synergistic effects when combined with conventional chemotherapies

  • Different effects in cancer vs. normal cells, suggesting therapeutic window

  • Activity in therapy-resistant models

• Clinical correlations:

  • Association of high PKMYT1 expression with poor outcomes supports targeting

  • Correlation with specific molecular subtypes helps identify patient populations

  • Relation to immune markers suggests potential immunotherapy combinations

This collective evidence establishes PKMYT1 as a promising therapeutic target, particularly in aggressive cancer subtypes with limited treatment options.

How can researchers develop and validate PKMYT1 antibodies for companion diagnostic applications?

Developing PKMYT1 antibodies as companion diagnostics requires specialized approaches:

• Antibody selection and optimization:

  • Evaluation of multiple clones for specificity and sensitivity

  • Optimization for diagnostic platforms (IHC, ELISA)

  • Determination of optimal cutoff values for patient stratification

  • Development of standardized scoring systems

• Analytical validation:

  • Assessment of precision (repeatability, reproducibility)

  • Determination of analytical sensitivity and specificity

  • Evaluation of pre-analytical variables (fixation, processing)

  • Establishment of reference standards

• Clinical validation:

  • Correlation with response to PKMYT1-targeting therapies

  • Determination of positive/negative predictive values

  • Assessment in retrospective and prospective clinical trials

  • Comparison with alternative biomarker approaches

• Regulatory considerations:

  • Design validation studies to meet regulatory requirements

  • Documentation of development process

  • Quality management system implementation

  • Coordination with therapeutic development timeline

These steps establish the foundation for PKMYT1 antibody-based diagnostics that could identify patients most likely to benefit from PKMYT1-targeted therapies or combination approaches.

How should researchers interpret conflicting PKMYT1 antibody results across different experimental platforms?

Resolving discrepancies between PKMYT1 antibody results requires systematic analysis:

• Sources of potential discrepancies:

  • Epitope accessibility differences between techniques

  • Post-translational modifications affecting antibody recognition

  • Differential expression of PKMYT1 isoforms

  • Sample preparation differences affecting protein conformation

• Resolution approaches:

  • Use multiple antibodies targeting different epitopes

  • Validate with orthogonal techniques (e.g., mass spectrometry)

  • Perform knockout/knockdown controls in each experimental system

  • Systematically test sample preparation variables

• Platform-specific considerations:

  • WB vs. IHC: Compare denatured vs. native conditions

  • Flow cytometry vs. IF: Assess permeabilization effects

  • ELISA vs. IP: Evaluate buffer compatibility issues

• Analytical strategies:

  • Determine if discrepancies are quantitative or qualitative

  • Assess relationships between signal intensity and biological effects

  • Consider kinetic aspects (time-dependent changes)

  • Evaluate reproducibility within each platform before comparing across platforms

This methodical approach helps determine which results most accurately reflect true PKMYT1 biology and which may be artifacts of specific experimental conditions.

What strategies can address challenges in detecting low-abundance PKMYT1 in normal tissues?

Detecting low-abundance PKMYT1 in normal tissues presents specific challenges:

• Signal amplification techniques:

  • Tyramide signal amplification for IHC/IF

  • Enhanced chemiluminescence substrates for Western blotting

  • Proximity ligation assay for enhanced sensitivity

  • Sample concentration methods (immunoprecipitation before detection)

• Noise reduction approaches:

  • Extensive blocking to minimize background

  • Extended washing protocols to remove non-specific binding

  • Optimized antibody concentrations to maximize signal-to-noise ratio

  • Background subtraction in image analysis

• Sample preparation optimization:

  • Enrichment of relevant cell populations (FACS, laser capture microdissection)

  • Subcellular fractionation to concentrate target protein

  • Optimized extraction buffers for complete protein recovery

  • Minimized processing steps to prevent protein loss

• Controls and validation:

  • Careful selection of positive controls with known low expression

  • Spike-in experiments with recombinant protein

  • Parallel RNA detection methods (RT-qPCR, RNA-FISH)

  • Genetic models with tagged endogenous PKMYT1

These approaches increase the likelihood of detecting physiologically relevant PKMYT1 expression in normal tissues, which is essential for understanding its normal functions and potential therapeutic implications.

How can researchers effectively design experiments to investigate PKMYT1 phosphorylation dynamics in response to therapeutic agents?

Investigating PKMYT1 phosphorylation dynamics requires careful experimental design:

• Temporal considerations:

  • Establish detailed time-course experiments (minutes to hours)

  • Synchronize cells to specific cycle phases before treatment

  • Use pulse-chase approaches for phosphorylation turnover

  • Consider both acute and chronic drug exposure

• Technical approaches:

  • Use phospho-specific antibodies for key sites (pThr495, pSer83)

  • Apply phospho-proteomics for comprehensive site mapping

  • Employ mobility shift assays to detect global phosphorylation changes

  • Utilize FRET-based biosensors for real-time monitoring

• Validation strategies:

  • Phosphatase treatment controls to confirm specificity

  • Site-directed mutagenesis (phospho-mimetic and phospho-deficient)

  • Pharmacological inhibition of relevant upstream kinases

  • Correlation with functional outcomes

• Data analysis approaches:

  • Quantitative analysis with appropriate normalization

  • Kinetic modeling of phosphorylation/dephosphorylation rates

  • Correlation with cell cycle markers and cellular phenotypes

  • Integration with other signaling pathway data

This experimental framework enables researchers to map how therapeutic agents affect PKMYT1 regulation and function, potentially revealing mechanisms of drug action or resistance.